Evidence map›Paper›PMID 27235665›Full record

ReviewAdvanced drug delivery reviews2016

Graphene and the immune system: Challenges and potentiality.

Marco Orecchioni, Cécilia Ménard-Moyon, Lucia Gemma Delogu, Alberto Bianco

Abstract readReview
PubMed Publisher
In one paragraph

Review in Advanced drug delivery reviews, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Multifunctional inorganic nanomaterials for cancer photoimmunotherapy.Cancer communications (London, England) · 2022
    Review
  11. 2D Materials for Cardiac Tissue Repair and Regeneration.Frontiers in cardiovascular medicine · 2022
    Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Photodynamic Therapy Based on Graphene and MXene in Cancer Theranostics.Frontiers in bioengineering and biotechnology · 2019
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

Marco OrecchioniDepartment of Chemistry and Pharmacy, University of Sassari, 07100 Sassari, Italy.
Cécilia Ménard-MoyonCNRS, Institut de Biologie Moléculaire et Cellulaire, Laboratoire d'Immunopathologie et de Chimie Thérapeutique, 67000 Strasbourg, France.
Lucia Gemma DeloguDepartment of Chemistry and Pharmacy, University of Sassari, 07100 Sassari, Italy. Electronic address: lgdelogu@uniss.it.
Alberto BiancoCNRS, Institut de Biologie Moléculaire et Cellulaire, Laboratoire d'Immunopathologie et de Chimie Thérapeutique, 67000 Strasbourg, France. Electronic address: a.bianco@ibmc-cnrs.unistra.fr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the growing area of nanomedicine, graphene-based materials (GBMs) are some of the most recent explored nanomaterials. For the majority of GBM applications in nanomedicine, the immune system plays a fundamental role. It is necessary to well understand the complexity of the interactions between GBMs, the immune cells, and the immune components and how they could be of advantage for novel effective diagnostic and therapeutic approaches. In this review, we aimed at painting the current picture of GBMs in the background of the immune system. The picture we have drawn looks like a cubist image, a sort of Picasso-like portrait looking at the topic from all perspectives: the challenges (due to the potential toxicity) and the potentiality like the conjugation of GBMs to biomolecules to develop advanced nanomedicine tools. In this context, we have described and discussed i) the impact of graphene on immune cells, ii) graphene as immunobiosensor, and iii) antibodies conjugated to graphene for tumor targeting. Thanks to the huge advances on graphene research, it seems realistic to hypothesize in the near future that some graphene immunoconjugates, endowed of defined immune properties, can go through preclinical test and be successfully used in nanomedicine.

Indexed as

AnimalsAntibodiesBiosensing TechniquesGraphiteHumansImmune SystemMolecular Targeted TherapyNeoplasmsAntibodiesGraphiteAntibodyBiosensorsGrapheneImmune cellsImmune systemTumor targeting

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.